EOMES and myeloid sarcoma: B cells are an important driver of disease progression in MS by establishing a proinflammatory status through the production of inflammatory cytokines,20 the activation of T cells21,22 and the formation of lymphoid follicular structures in the meninges.23 B cell targeting anti-CD20 antibodies such as rituximab, ocrelizumab, ofatumumab and ublituximab are an effective therapeutic approach in MS.24-32 Neither B cell depletion nor other immunomodulating therapies showed an effect on frequencies of Eomes+ Th cells in our study.